This paper was presented at the Workshop on Air Toxics
and Asthma-Impacts and End Points held 4 February 1994 in Houston, Texas.
Manuscript received: January 17, 1995; accepted February 3, 1995.
Helpful comments on earlier versions of this paper were
provided by I. Cote, F. Hauchman, D. Kleffman, T. Miller, J. Vandenberg,
and H. Zenick. Early drafts were completed while the author was director
of U.S. EPA's Office of Health Research. The views expressed are solely
those of the author and do not necessarily represent the views or policies
of the U.S. EPA.
Address correspondence to Dr. Ken Sexton, Environmental
and Occupational Health, School of Public Health, University of Minnesota,
Box 807 UMHC, 420 Delaware Street, SE, Minneapolis, MN 55455. Telephone
(612) 626-4244. Fax (612) 626-0650.
Introduction
In the United States, there is a longstanding societal commitment to
safeguarding people's health from the adverse effects of toxic agents in
the environment. This is reflected in the missions, mandates, and actions
of federal regulatory agencies like the U.S. Environmental Protection Agency
(U.S. EPA), U.S. Food and Drug Administration (FDA), U.S. Occupational Safety
and Health Administration (OSHA), and U.S. Consumer Product Safety Commission
(CPSC). At the state level, there are also numerous regulatory agencies
that share responsibilities for regulating risks from toxic exposures. Regulatory
decision making is defined here to mean the kinds of decisions that
these regulatory agencies must make to balance trade-offs between economic
and societal costs of government intervention on one hand and corresponding
benefits to public health or environmental quality on the other.
This article looks at how science is used in making regulatory decisions
and examines Title III of the 1990 Clean Air Act Amendments as a case study.
The discussion is divided into two major sections: a general survey of regulatory
decision making with emphasis on the role of science and an examination
of the hazardous air pollutant provisions of the Clean Air Act.
Survey of Regulatory Decision Making
It is useful, at the outset, to examine the conceptual framework for
regulatory decisions, keeping in mind that practical realities often intervene
to make real-world decisions more complicated and harder to analyze.
Science Policy: The Interface between Science and Policy
In the process of regulatory decision making, there is a direct interface
between science and policy. Science is used here in its broadest sense to
encompass research and development, technical and research support, monitoring
and data collection, review and interpretation of technical investigations,
and assessments of health and environmental risks. Policy is used to mean
decisions both about the acceptability of risks and about the tradeoffs
between the costs and benefits of intervention to prevent and reduce
unacceptable risks. The interface between science and policy has been called
science policy, and in the context of regulatory decision making, it has
two complementary meanings (1,2): the use of science to make judgments
about the formulation and implementation of policy (e.g., quantitative risk
assessment), and the development of policy specifically for science
(e.g., setting priorities for research directions and funding).
As depicted in Figure 1, science and policy can be conceptualized as
existing on opposite ends of a fact-value continuum. Science is portrayed
as primarily factual, with a smaller but important value component, while
policy is comprised primarily of values, with a smaller but important factual
component. Science policy exists at the intersection between facts and values,
often functioning in the area where scientific knowledge and understanding
are incomplete. This means that judgments, inferences, and extrapolations
are a necessary aspect of most, if not all, science policy decisions.


Figure 1. Conceptual
framework for the interrelationships between science, science policy, and
policy (fact-value continuum).
Relationships among Research, Risk Assessment, and Risk Management
According to the National Research Council (3,4) and the Office
of Technology Assessment (5), regulatory decision making can be thought
of as occurring in three phases: a) research to provide necessary
scientific information and understanding;
b) risk assessment, either qualitative or quantitative, to estimate
the likelihood, magnitude, and uncertainty of risks; and c) risk
management to make determinations about the risks that are unacceptable
and what, if anything, to do about them. A fourth element, risk communication,
is becoming increasingly important, and refers to the need for regulatory
agencies to enter into a dialogue with stakeholders to explain risks and
risk-related actions, and to respond to their concerns and questions (6).
In a landmark 1983 report, Risk Assessment in the Federal Government:
Managing the Process, the National Research Council (NRC) argues against
organizational separation but calls for clear conceptual distinctions between
research, risk assessment, and risk management (3). In the NRC view,
research provides the factual, presumably valueless, basis for risk assessment.
Risk assessment uses scientific facts to estimate risks, but because
the scientific database is incomplete, there are "decision points
where risk can only be inferred from available data." These decision
points require "scientific judgments and policy choices"
to select among alternative inferential bridges. The NRC calls these choices
risk assessment policy. Risk management integrates the results of risk assessment
with engineering data and social, economic, and political considerations
to weigh policy alternatives and to select an appropriate course of action.
The NRC labels these choices risk management policy.
The NRC suggests, "At least some of the controversy surrounding
regulatory actions has resulted from the blurring of the distinction between
risk assessment policy and risk management policy." The Council notes,
however, that the most important contributor to the conflict and controversy
surrounding regulatory decisions is the differing values placed on the relative
importance of economic costs versus health benefits by different segments
of society.
Because of the contentiousness of many regulatory decisions, the NRC
expresses concern "that scientific interpretations in risk assessment
will be distorted by policy considerations." Partially in response
to these concerns, the Council recommended "reorganization to ensure
that risk assessments are protected from inappropriate policy influences
and development and use of uniform guidelines for carrying out risk assessments."
The NRC made it plain that "The importance of distinguishing between
risk assessment and risk management does not imply that they should be isolated
from each other; in practice they interact, and communication in both directions
is desirable and should not be disrupted."
Although the NRC pointed out the problems associated with organizational
separation and emphasized the need for communication among researchers,
risk assessors, and risk managers, the 1983 report has served as the rationale
to justify compartmentalization of regulatory decision making. As summarized
in Figure 2, the NRC made clear conceptual distinctions between research
and risk assessment and between risk assessment and risk management. Both
conceptual and organizational distinctions among these different phases
are now well-entrenched within many federal bureaucracies.

Figure 2. The
traditional risk assessment paradigm and its relationship to the fact-value
continuum. Adapted from the National Research Council (3).
Nevertheless, an increasing number of observers question (or reject outright)
this separation of facts (science) and values (policy). They argue that,
in reality, science and policy are inseparable, and they find no rational
basis for the existing compartmentalization, which they view as artificial,
arbitrary, and counterproductive. These critics contend that formal integration
of science and policy is necessary to foster better and more consensual
societal decisions about environmental health risks (2,7-10).
An alternative to the more traditional approach (Figure 2) for conceptualizing
the key aspects of regulatory decision making is pictured in Figure 3. In
this conceptual model, the three phases are not portrayed as either completely
separate or wholly integrated. Instead, they are pictured as overlapping
spheres, each with its own focus. The role of values, both personal and
societal, is acknowledged and made explicit within the context of each sphere.
The emphasis shifts from facts to values as one moves from science to policy
(left to right) along the research-risk
assessment-risk mangagement continuum.

Figure 3. An alternative
risk assessment paradigm and its relationship to the fact-value continuum.
Adapted from Sexton et al. (12).
This alternative paradigm explicitly emphasizes that interrelationships
among scientific research, risk assessment, and risk management should
form a feedback loop to foster more informed judgments (11,12). The
feedback loop requires that information, including facts and values, flow
in two directions. First, the information needs identified as part
of risk assessment and risk management must drive the direction and nature
of supporting research. Second, the information and understanding generated
by the research program must directly improve the scientific basis
for decisions.
Different Roles for Scientists and Regulators
Science is an integral part of regulatory decision making and its role
is 2-fold: to improve the quantity and quality of scientific information
and to enhance our ability to interpret the available scientific database
for risk assessment, risk management, and risk communication decisions.
Scientists not only conduct research (generating facts), but many also play
a critical role in science policy (judgments about the use of facts) by
serving as technical consultants, peer reviewers, policy advocates, and
mediators (2).
A major role of scientists in the regulatory process is to provide expert
advice about science policy issues, e.g., validation of long-term research
strategies, certification of study protocols and analytical methodologies,
definition of standards of adequacy for scientific evidence, and
approval of inferences from studies and experiments (2). The lack
of scientific certainty normally associated with science policy issues
puts a premium on scientific consensus. In the face of significant
uncertainty regarding issues such as the adequacy of scientific evidence
and the appropriateness of inferences from existing data, consensus among
a diverse spectrum of respected scientists functions as a stabilizing factor
and intellectual anchor; it focuses attention on critical, unresolved technical
questions and lends credibility to both the process and
its products.
In contrast to the scientist, the regulator must go beyond consideration
of the scientific facts supporting the decision process. The challenge
of regulating risk involves balancing science, values, and economics. Other
factors such as legislative mandates and political considerations can also
play a major role in shaping regulatory decisions. Six major categories
of information essential to risk managers are (13)
- Science
- public health and ecological risks
- technical feasibility of risk management options
- Law
- legislative mandates
- regulatory options
- Economics
- costs and benefits
- economic feasibility of risk management options
- Public Values
- public sensitivity to risk
- credibility of risk management options
- Communication
- public and stakeholder involvement
- communication strategy for risk management options
- Politics
- political importance of risk
- political acceptability of risk manage-ment options.
Ideally, science (along with public values and economics) is an important
factor in regulatory decision making. When scientific knowledge and
understanding are insufficient to answer important regulatory-related
questions, there is typically a controversy about "whether regulators
have the facts right." Moreover, there is typically widespread concern
that without a firm scientific foundation, regulatory decisions
can be more easily driven by political agendas, media pressure, special
interests, legal challenges, and bureaucratic inertia.
An obvious solution is to invest adequate resources in targeted research
and surveillance to reduce the most critical scientific uncertainties
that currently limit our ability to estimate risks realistically. Although
the roles of the scientist and regulator may be different, it is clear that
they share a common goal--the reduction of scientific uncertainty to
improve the assessment of health and environmental risks (14-16).
Viewpoints on the Value of Science
Focusing on the practical realities of real-world regulatory decisions,
divergent viewpoints have emerged about the intrinsic value of science in
the politically and emotionally charged atmosphere that surrounds many environmental
health issues such as neighborhood cancer clusters, Alar-contaminated apples,
and asbestos in schools. Generally speaking, opinions about the relative
importance of science (e.g., data on exposure and toxicity) in regulatory
decision making can be grouped into three broad categories (Figure 4): a)
science is a critical, often central, factor in decisions (17-20);
b) science plays a marginal and often insignificant role in
what are basically political decisions (2,21-23); and c) science
is one of several factors in a multifactorial decision-making process (8,9,21,24).

Figure 4. Different
viewpoints about the role of
science in regulatory decision making.
The traditional view, consistent with the risk assessment paradigm (3),
has been that science (research) is an essential driving force underpinning
regulatory decisions, and that better science (facts) leads directly to
better decisions about management of risks. Some observers, however, have
taken a more skeptical view, seeing decisions about risk as essentially
a political (value) exercise wherein science rarely plays a decisive role.
These observers remind us that science cannot provide definitive and
timely answers to most of the crucial questions confronting decision makers,
and they argue that science can be fragmented and polarized by the beliefs
and values of special interests being used to legitimize political agendas
rather than to illuminate and inform the debate.
A third, more middle-of-the-road viewpoint is that science is just one
of many important factors in regulatory decision making. According to this
view, the major contributions of science to decision making are its unique
capabilities to structure and describe critical technical issues, especially
as they relate to other important decision variables, and to identify and
address key scientific uncertainties in risk assessment. Scientists
are seen as vested with a special responsibility to guard against distortions
and misuse of scientific evidence, which might unfairly bias the process.
Whether science is the central factor or only a marginal consideration
in the final regulatory decision, it should be an explicit part of
the public debate about the seriousness and acceptability of environmental
health risks. Scientific evidence can enhance and inform the debate
and lend credibility to regulatory decisions.
Factors Affecting the Role of Science in Regulatory Decisions
The role that science plays in regulatory decision making depends on
certain characteristics of the situation. Although this issue has received
little attention, it is evident that situational variables such as media
scrutiny, public outrage over perceived risks, political pressure to do
something, legal requirements and deadlines, and the degree of scientific
consensus about risks and remediation measures affect how and to what extent
science infiuences decisions. Three of the potentially more significant
situational variables are the age of the relevant public policy issue, the
boundary-crossing implications of the science, and the bureaucratic realities
of real-world pressures and demands on regulatory decision makers.
Conceptually, public policy issues can be thought of as passing through
a four-stage lifecycle: identification, politicalization, legislation,
and litigation (Figure 5). Science is apt to play different roles depending
on the age (life-cyle stage) of the policy issue at hand. For example, in
the identification stage, science usually provides a sense of the magnitude,
scope, and uncertainty of the problem, while in the litigation stage, science
primarily documents compliance or noncompliance with established guidelines,
standards, and regulations.

Figure 5. Simplified
life cycle of a public policy issue.
Another factor of likely importance is the potential for science (or
scientific consensus) to displace estimates of risk from one region
of social acceptability to another (Figure 6) (25). Science can be
thought of as having boundary-crossing implications when it could alter
risk estimates in a way that makes them either more or less acceptable according
to prevailing societal norms. For example, research might precipitate a
change in an estimated risk such that it moves from being socially acceptable
(e.g., probability less that one in a million) to being selectively unacceptable
(e.g., probability greater that one in a million), or vice versa. Science
with boundary-crossing implications is more likely to play a central role
in regulatory decisions and, for that reason, to be more contentious.

Figure 6. Conceptual
framework for the boundaries between different levels of socially acceptable
risk. Adapted from Kolluru (25).
Finally, as a practical matter, regulatory decision makers respond to
the realities imposed on them by a complex and constantly changing environment
(Figure 7A) (26-29). Among the more important factors that
can affect their decisions are political pressures, statutory mandates,
institutional constraints, scientific and technical issues, public
perceptions, and special interests. The exigencies created by confrontations
between these often conflicting forces have fostered an informal decision
process that is, among other things, subjective, messy, uncertain, unstructured,
intuitive, pressured, contentious, and chaotic (Figure 7B).

Figure 7. Schematic
representation of (A) the diversity of forces affecting regulatory
decision makers and (B) the informal, ad hoc process for making regulatory
decisions.
The people who staff and run this "adhocracy" tend to exhibit
common bureaucratic tendencies, which can have significant ramifications
for the final outcome;
- A tendency to make conservative decisions (err on the side of safety);
- A reluctance to change (subject to bureaucratic inertia);
- A tendency to seek/build consensus (credibility depends on consensus);
- A reliance on codified rules (prefer standard, published procedures);
- A tendency to delay decisions (don't decide until forced);
- A dislike of surprises (fear that revelations can only be bad);
- A tendency to act in self interest (consider impact on career); and
- A response to personalities (prefer working with certain people).
In a recent study (29) of the kinds of information that U.S. EPA decision
makers want to have when making a decision, it was found that they wanted
data on risk assessment issues such as numerical estimates of risk, magnitude
of adverse effect,
level of exposure, and confidence in data. In addition, they also want to
have a sense of the bureaucratic context and possible institutional ramifications
of their actions (or inactions). For example, they want to know the consequences
of doing nothing; reactions of stakeholders to recommended options; costs
and economic impacts; what has been done in previous, similar situations;
and positions of other U.S. EPA offices and the Office of Management
and Budget.
In the final analysis whether science is a force or has any effect at
all depends to a large extent on this real-world calculus involving conflicting
forces, informal and ad hoc decision processes, and bureaucratic tendencies
of decision makers. Because the dynamics of these complex interactions are
constantly changing, the role of science can vary dramatically from one
situation to the next. Understanding when and why this is true is important
for identifying ways to increase the utility of regulatory-related science
in decision making.
The Science and Policy of Hazardous Air Pollutants:
A Case Study
The hazardous air pollutant provisions of the 1990 Clean Air Act Amendments
offer an example of how politics can dominate the debate when there are
inadequate facts about risks and benefits.
Practical Realities of Title III
With relatively little fanfare, the 1990 Clean Air Act Amendments (CAAA)
were signed into law by President Bush on 15 November 1990 (30).
The passage of the CAAA by the U.S. Congress involved intense and protracted
negotiation over complex political issues and ultimately was dependent on
political compromise among powerful members with diametrically opposed views,
interests, and constituencies (31,32). The result is a complicated
and detailed piece of legislation that combines traditional approaches such
as command-and-control with some new innovations like market-based incentives
(31-35).
The CAAA provide a comprehensive regulatory framework for clean air.
They take a primarily prescriptive approach and mandate an immense, technology-based,
regulatory effort driven by tight deadlines for compliance. The 1990 regulations
create new or modified programs to address acid rain, stratospheric
and tropospheric ozone, vehicle emissions, and hazardous air pollutants
as well as establish a uniform national permitting system. Eventually the
requirements associated with implementation of the CAAA will affect virtually
every industrial source in the United States and are expected to fill
6000 pages of U.S. code books, compared with 9000 pages for all other environmental
codes combined (34).
Title III of the 1990 Clean Air Act Amendments addresses the issue of
hazardous air pollutants from stationary and urban area sources. Hazardous
air pollutants are those not defined as criteria pollutants under Title
I. Among the more significant provisions of Title III are a)
a list of 189 substances (and classes of substances) deemed to be hazardous
air pollutants; b) requirements to identify and prioritize major
sources of these chemicals; c) a mandate to apply maximum achievable
control technology (MACT) to major sources over the next 10 years; d)
spec-
ification that, subsequent to applying MACT, an analysis of residual
risk must be performed to determine if further actions are needed to protect
human health;
e) establishment of an area source program aimed at reducing the
incidence of cancer attributable to urban area sources by 75%; f)
formation of a risk assessment and management commission composed of 10
scientific experts to examine how risk assessment and risk management
are used to make decisions about clean air; and g) initiation of
a National Academy of Sciences (NAS) study on risk assessment (4).
The political decision behind Title III is apparent: emissions of hazardous
air pollutants pose a threat to public health that is sufficient to
justify the costs of applying MACT. This suppostion is not founded on hard
scientific evidence or rigorous cost-benefit analysis but rather
on a political consensus that instead of waiting for a body count, it is
prudent public policy to take regulatory action to reduce postulated, if
highly uncertain, air pollution health risks. The approach taken in Title
III, to apply MACT and then see if residual risks are unacceptable, reflects
congressional frustration with what it perceives to be the slow pace of
hazardous air pollutant regulation under the risk-based provisions of the
1977 Clean Air Act Amendments; only seven hazardous air pollutants were
regulated prior to 1990.
In contrast to the political consensus that hazardous air emissions represent
an unacceptable health risk, the scientific basis for estimating risks
from outdoor exposure to hazardous air pollutants is fragmented and sparse.
Preliminary estimates by U.S. EPA suggest that as many as 2500 cancer cases
per year may result from outdoor exposure to 45 of the 189 hazardous air
pollutants (36), although some researchers have criticized that estimate
as being too high (37). In addition, it has also been suggested that
noncancer health effects from outdoor exposure to hazardous air pollutants,
including nonmalignant respiratory disease, hematopoietic abnormalities,
neurotoxicity, renal toxicity, and reproductive and developmental toxicity,
may be widespread. Approximately 50 million people live near emission sources
where estimated ambient concentrations of one or more hazardous air pollutants
exceed levels of concern for noncancer health effects in humans (38).
Overall, however, a paucity of data exists to support accurate estimates
of actual exposures, doses, and health consequences for either the general
population or for communities potentially at greater risk.
The available data on the 189 hazardous air pollutants regulated under
Title III are summarized in Figure 8. Based on an analysis conducted by
U.S. EPA (39), adequate data are currently available on only a small
percentage of these chemicals. For example, fair or better evidence exists
to estimate emissions for only 17 substances, ambient concentrations for
43, noncancer health effects for 27, and carcinogenicity for 88. Inadequate
data are on hand to estimate emissions for 137 substances, ambient concentrations
for 112, noncancer effects for 149, and carcinogenicity for 81 (39).

Figure 8. Summary
of the adequacy of available data on 189 hazardous air pollutants. Adapted
from U.S. EPA (39).
Given the inadequacy of the scientific database, the resulting uncertainty
about air pollution health risks, and the enormous costs of implementing
the regulations, there has been surprisingly little criticism of the 1990
Clean Air Act Amendments in general and of Title III in particular (33,34,40).
Currently, both critics and supporters of the amendments appear to see them
as a significant step toward achieving the goal of clean air. As the
costs become more apparent, however, the benefits of the CAAA will
come under increasing scrutiny (41-46).
Insight into the regulators' perspective on the public health benefits
of the CAAA is provided by the following quotes. Lydia Wegman, Deputy Director,
Office of Air Quality Planning and Standards, Office of Air and
Radiation, U.S. EPA, states that
...The [hazardous air pollutant] program will substantially decrease
the number of cancer cases caused by air pollution, and it will reduce many
other health effects. Consequently, medical costs associated with these
effects will be substantially diminished (47).
Robert Brenner, Director, Office of Policy Analysis and Review,
Office of Air and Radiation, U.S. EPA, said
...I'm confident that the act is going to be, if not fully implemented,
virtually fully implemented....All significant emission reductions
will be attained....55 billion pounds a year of emission reductions when
the [Clean Air Act] is fully phased in after the year 2000. That is enough,
we believe, to have a pretty dramatic effect on people's health (34).
According to Mary D. Nicols, Assistant Administrator, Office of
Air and Radiation, U.S. EPA,
Today is the third anniversary of the Clean Air Act Amendments of 1990.
In the course of those 3 years, the Act has noticeably improved public health
and the environment (M Nichols, personal communication).
Despite the scarcity of data, these regulatory officials seem confident
that improvements in public health have occurred already and that they will
continue to acrue in the future from implementation of the CAAA. Their optimism
appears to be based on the assumption that a direct relationship exists
between regulatory actions and related emissions reductions and between
emissions reductions and reduced health risks (Figure 9). Under this assumption,
keeping score of the public health benefits is possible by tallying
the number of major regulatory actions taken (Figure 9B), summing
the estimated reduction in emissions related to these actions (Figure 9A),
and then calculating the estimated decrease in cancer risk based on standard
EPA approaches (Figure 9C). This assumption may, however, have no
basis in fact and, without appropriate data, cannot be verified (4,48,49).

Figure 9. Summary
of U.S. EPA perspective on the 1990 Clean Air Act Amendments: (A)
air emissions reductions to date in billions of pounds per year; (B)
number of major regulatory actions; and (C) effect of technology
standards on cancer risks from stationary sources. (A,B) from U.S.
EPA (52); (C) from Wegman (47).
All this suggests that it would be difficult to argue that Title
III of the 1990 Clean Air Act Amendments is science driven. The scientific
information and understanding necessary to quantify the risks from outdoor
exposure to hazardous air pollutants with a reasonable degree of certainty
are simply unavailable in most cases. In their absence, adequate political
concern and consensus among elected officials is sufficient to
drive regulatory action. Although the public health benefits are uncertain,
a political decision has been made to get on with the business of cleaning
the air.
Research in Support of More Informed and More Credible Decisions
Within this milieu, what is the role of scientific research in Title
III? One way to think about this question is to envision a continuum of
relevant research (Figure 10A) covering: a) routine testing
and monitoring to meet statutory requirements;
b) research aimed at reducing uncertainties in risk assessment; and
c) research focusing on broad strategic issues. Keeping in mind that
these three research directions are not mutually exclusive, characteristics
generally associated with each are listed in Figure 10B. A combination
of all three research approaches is necessary to establish a firm and
credible foundation for informed decision making (Figure 10C).

ABCFigure 10.
Conceptual framework for research to strengthen the scientific basis for
Title III of the 1990 Clean Air Act Amendments: (A) directions, (B)
characteristics, and (C) framework.
Research to meet key statutory requirements is usually the top priority
for regulators since theirs is the task of implementing the statutes. Typically,
this type of work consists primarily of filling key data gaps by testing
for cancer or noncancer effects in animals, measuring or estimating emissions,
and monitoring ambient concentrations to determine compliance. This type
of research is generally of short duration and the emphasis is on doing
things right.
The need for research to reduce uncertainties in risk assessment is pervasive,
long standing, and widely acknowledged (3,4,15,16). Without progress
in this area, health-related benefits of risk reduction or prevention
remain largely speculative. Quantitative risk assessment is impeded in most
cases by two persistent problems; lack of data and lack of understanding.
These problems contribute to uncertainty in risk assessments by causing
errors in estimating important parameters accurately, in identification
of relevant hazards or causal pathways, in specifying the functional form
of models, and in extrapolating from one set of conditions to another. Research
to address the first problem (lack of data) emphasizes improvement
of the quality and quantity of the scientific database, while research
to address the second problem develops and applies mechanistically based
methods and models (12,16).
Research to address strategic issues examines whether we are asking the
right questions and how science can be more effective in informing the debate.
The emphasis is on doing the right things and typically requires a long-term
commitment of resources. This type of research is important because it can
challenge existing dogma, cause paradigm shifts, and create the need for
new priorities and directions.
In a mature program such as Title III, late in its lifecycle as a public
policy issue (Figure 5) regulatory emphasis is likely to be on research
to meet statutory requirements. This may be tempered somewhat by the fact
that Title III also has several provisions that seem to create an explicit
need for research to reduce risk assessment uncertainties, including regulatory
requirements to a) list or delist chemicals (Section 112(b)); b)
prioritize source categories (Section 112(c)); c) delist source categories
(Section 112(c)); d) establish regulations for modified sources
(Section 112(g));
e) implement the urban area source program (Section 112(k)); f)
promulgate standards to protect public health and the environment (Section
112(f)); and g) promulgate accidental release regulations and guidance
(Section 112(r)) (50).
At this stage, regulatory enthusiasm for research to address broad, strategic
questions appears to be minimal. Given the political consensus behind passage
of the CAAA and the regulators' apparent confidence that the benefits
are worth the costs, and considering inherent bureaucratic tendencies toward
caution and inertia (Figure 7), there are few incentives for regulatory
officials and policy makers to encourage this kind of research. For
example, no comprehensive research program is in place to determine whether
the list of 189 hazardous air pollutants in Title III is appropriate or
relevant from a public health perspective or to evaluate whether risks from
outdoor exposure to toxic air pollutants justify the costs of technology-based
controls.
Research notwithstanding, the philosophy and approach to controlling
hazardous air pollutants embodied in Title III may remain fixed well
into the 21st century. As the costs of regulating scientifically uncertain
health risks become better defined and more understood, questions of
whether we are doing the right things become pivotal (41-46). Just
because the political issues seem to be settled does not mean that we should
walk away from the crucial scientific issues. By failing to address
the critical strategic questions now, we ensure that in the future we will
continue to lack a sufficient scientific foundation for determining
whether we are doing the right things for the right reasons.
Developments outside or only peripherally related to the CAAA, including
scientific and technical innovations, new developments in science-policy
judgments, or changes in policy positions, could potentially disrupt the
existing political consensus about hazardous air pollutants. Among the types
of changes that might have significant ramifications for Title
III are the following: the expanding technical capability and feasibility
to measure biological markers of exposure, susceptibility, and dose in humans;
advances in our understanding of the etiology of currently ill-defined
and poorly understood chemical sensitivity syndromes such as multiple chemical
sensitivity, sick building syndrome, and building-related illness; breakthroughs
in our ability to measure or estimate the health effects of chemical mixtures;
increasing emphasis on risk-based priority setting (addressing the worst
risks first) to establish budgetary, regulatory, and research priorities;
improvements in methods and models to determine total exposures to air pollution,
thereby allowing us to apportion the contribution to exposure of various
sources and pathways; and better information and understanding about the
extent to which economically disadvantaged communities, including many ethnic
and racial groups, are disproportionately at greater cumulative risk from
air pollution exposures (e.g., issues of environmental justice).
Summary and Conclusions
Facts and values are important building blocks of regulatory decisions.
Regulatory decision making incorporates these elements into an interconnected
series of overlapping phases--research (science), risk assessment (science
policy), and risk management (policy). These three phases should form a
feedback loop, with risk assessment and risk management driving research
directions and research providing scientific knowledge and understanding
as the basis for more credible and informed decisions.
Views about the utility of science in regulatory decision making cover
a wide spectrum, from those who see science as central and decisive to those
who believe it is marginal or insignificant. As a practical matter,
science is one of several variables in a multifactorial decision process.
Its utility varies according to certain key situational variables such as
the age of the public policy issue, the boundary-crossing implications of
the science, and the bureaucratic realities of regulatory decision making.
The hazardous air pollutant issue provides an illustration of political
consensus about the need for regulation despite the lack of scientific
evidence about risks and benefits. Hazardous air pollutants are regulated
under Title III of the 1990 Clean Air Act Amendments in a two-stage process.
First, technology-based standards to limit emissions are applied to important
sources. Second, residual risk characterization is conducted after installation
of maximum achievable control technology to determine whether further emission
reductions are necessary. This regulatory approach is not based on hard
scientific evidence of health risks or on rigorous cost-benefit
analysis. Instead, the approach is based on a political decision by Congress
that to wait for a body count before taking action would not be in the public
interest.
Because political consensus, which is often tenuous, is not necessarily
synonymous with scientific consensus, research should not be stymied
by the politics of clean air. In the face of significant uncertainties
about the public health benefits of Title III, a comprehensive research
program should be undertaken to establish a solid, credible scientific
basis for decision making. This would necessarily involve a balanced approach
that includes research to meet statutory deadlines, to reduce uncertainties
in risk assessment, and to answer key strategic questions.
Because strategic research has the potential to challenge dogma, shift
paradigms, and reorder priorities, it may not engender much political and
bureaucratic support. Nevertheless, the need for strategic research is getting
stronger as concerns mount about the relative costs and benefits of
regulating uncertain health risks. Informed, cost-effective protection of
public health requires a blending and balancing of facts and values. If
we are to get the facts right, investing in sound science is essential.
REFERENCES
1. Brooks H. The scientific advisor. In: Scientists
and National Policy Making (Gilpin R, Wright C, eds). New York: Columbia
University Press, 1964.
2. Jasanoff S. The Fifth Branch: Science Advisers as Policymakers.
Cambridge, MA:Harvard University Press, 1990.
3. National Research Council, National Academy of Sciences.
Risk Assessment in the Federal Government: Managing the Process. Washington:National
Academy Press, 1983.
4. National Research Council, National Academy of Sciences.
Science and Judgement in Risk Assessment. Washington:
National Academy Press, 1994.
5. Office of Technology Assessment. Health risk research.
OTA-BBS-570. Washington:U.S. Government Printing Office, 1993.
6. National Research Council, National Academy of Sciences.
Improving Risk Communication. Washington:National Academy Press, 1989.
7. Jasanoff S. Bridging the two cultures of risk analysis.
Risk Anal 13:123-129 (1993).
8. Mayo DG. Sociological versus metascientific views
of risk assessment. In: Acceptable Evidence: Science and Values in Risk
Management (Mayo DG, Hollander RD, eds). New York: Oxford University Press,
1991;249-279.
9. Shrader-Frechette K. Reductionist approaches to risk.
In: Acceptable Evidence: Science and Values in Risk Management (Mayo DG,
Hollander RD, eds). New York:Oxford University Press, 1991;218-248.
10. Silbergeld EK. Risk assessment and risk management:
an uneasy divorce. In: Acceptable Evidence: Science and Values in Risk Management
(Mayo DG, Hollander RD, eds). New York: Oxford University Press, 1991;99-114.
11. Sexton K. The role of scientific research in risk
assessment and risk management decisions. Otolaryngol Head Neck Surg 106:635-641
(1992).
12. Sexton K, Olden K, Johnson BL. Environmental justice:
the central role of research in establishing a credible scientific
foundation for informed decision making. Toxicol Ind Health 9:685-727 (1993).
13. Burke TA. Regulating risk: the challenges ahead. In:
Regulating Risk: The Science and Politics of Risk (Burke TA, Tran NL, Roemer
JS, Henry CJ, eds). Washington:International Life Sciences Institute, 1993.
14. Graham JD. Resolving the regulatory science dilemma.
In: Harnessing Science for Environmental Regulation (Graham JD, ed). New
York:Praeger Publishers, 1991;211-224.
15. Burke TA, Sexton K. Integrating science and policy
in a national human exposure assessment survey. J Int Soc Expo Anal (in
press).
16. Sexton K, Reiter LW, Zenick H. Research to strengthen
the scientific basis for health risk assessment: a survey of the context
and rationale for mechanistically based methods and models. Toxicology (in
press).
17. Reilly WK. Aiming before we shoot; the quiet revolution
in environmental policy. Rpt No 20Z-1011. Washington:U.S. Environmental
Protection Agency, 1990.
18. Graham JD. Science and environmental regulation. In:
Harnessing Science for Environmental Regulation (Graham JD, ed). New York:Praeger
Publishers, 1991;1-9.
19. U.S. EPA. Safeguarding the future: credible science,
credible decisions. EPA/600/9-91/050. Washington:U.S. Environmental Protection
Agency, 1992.
20. Browner CM. Protecting the environment: EPA's role
(letter). Science 261:1373 (1993).
21. Crandall RW, Lave LB. Introduction and summary. In:
The Scientific Basis of Health and Safety Regulation (Crandall RW,
Lave LB, eds). Washington:The Brookings Institution, 1981;17.
22. Clark WC, Giandomerico G. The critical appraisal of
scientific inquiries with policy implications. Sci Technol Human Values
10:6-19 (1985).
23. Golay MW. Quality of EPA research (letter). Science.
263:1669-1670 (1994).
24. Ashford NA. Science and values in the regulatory process.
Statistical Science 3:377-383 (1988).
25. Kolluru RV. Risk assessment and management. In: Environmental
Strategies Handbook: A Guide to Effective Policies and Practices (Kolluru
RV, ed). New York: McGraw-Hill, 1994;327-432.
26. Kimm VJ, Kuzmack AM, Schnare DW. Waterborne carcinogens:
a regulator's view. In: The Scientific Basis of Health and Safety Regulation
(Crandall FW, Lave LB, eds). Washington: The Brookings Institution, 1981;229-249.
27. Landy MK, Roberts MJ, Thomas SR. The Environmental
Protection Agency: Asking the Wrong Questions. New York: Oxford University
Press, 1990.
28. Skrzycki C. An 11th-hour call drives EPA bargain with
automakers. Washington Post, 1 February 1994.
29. Bloom DL, Byrme DM, Anderson JM. Communicating Risk
to Senior EPA Policy Makers: A Focus Group Study. Washington:U.S. Environmental
Protection Agency, 1993.
30. Clean Air Act Amendments of 1990. 42 U.S.C. 7401; P.L.
101-549, 15 November 1990.
31. Cohen RE. Washington at Work: Back Rooms and Clean
Air. New York:Macmillan Publishing Company, 1992.
32. Bryner GC. Blue Skies, Green Politics: The Clean Air
Act of 1990. Washington:Congressional Quarterly Press, 1993.
33. Ruch RB, Howell JS. Proactive industrial strategies
for the clean air act amendments of 1990. J Air Waste Manage Assoc 41:922-927
(1991).
34. McIntosh H. Catching up on the clean air act. Environ
Health Perspect 101:226-229 (1993).
35. Schulze RH. The 20-year history of the evolution of
air pollution control legistation in the U.S.A. Atmos Environ 27B:15-22
(1993).
36. U.S. EPA. Cancer risk from outdoor exposures to air
toxics. EPA-450/1-90-004A. Washington:U.S. Environmental Protection Agency,
1990.
37. Gray GM, Graham JD. Risk assessment and clean air policy.
J Policy Anal Manage 10:286-295 (1991).
38. Hasset-Sipple B and Cote I. Toxic air pollutants and
noncancer health risks. Morb Mortal Wkly Rep 40:278-279 (1990).
39. U.S. EPA. EPA's urban area source research program:
preliminary research report. Washington:U.S. Environmental Protection Agency,
1994.
40. Wolfe DE, Lamb LM. Clean air act amendments offer substantial
savings. The National Environmental Journal September/October:32-36 (1991).
41. Brookes W. EPA's high cost of political science. Washington
Times, 16 December 1991.
42. Davis B. What price safety? risk analysis measures
need for regulation, but it's not science. Wall Street Journal, 6 August
1992.
43. How a rebellion over environmental rules grew from
a patch of weeds. New York Times, 24 March, 1992.
44. House stalls on EPA status, cites costs. Washington
Times, 3 February 1994.
45. Lang RA. National risk assessment policy could aid
government decision-making. Hazmat World October:71-73 (1993).
46. Meet the Clean Air Act monster. Wall Street Journal,
1 February 1994.
47. Wegman L. Air toxics: the strategy. EPA J 17:32-33
(1991).
48. National Research Council, National Academy of Sciences.
Human exposure assessment for airborne pollutants; advances and opportunities.
Washington:National Academy Press, 1991.
49. National Research Council, National Academy of Sciences.
Frontiers in assessing human exposures to environmental toxicants. Washington:National
Academy Press, 1991;246-249.
50. Hauchman FS. The role of risk assessment in Title III
of the 1990 Clean Air Act Amendments. In: Proceedings of the Conference
on Air Toxics Issues in the 1990s: Policies, Strategies, and Compliance.
Pittsburgh, PA:Air and Waste Management Association, 1991;73-80.
51. U.S. EPA. Strategy for the Clean Air Act Amendments
of 1990 (Update 1993). Washington:Office of Air and Radiation, 1993.
[
Table
of Contents]
Last Update: September 15, 1998